Dynamics of HBV markers during nucleotide analogue treatment

Dynamics of HBV markers during nucleotide analogue treatment - Dynamics of HBV markers during nucleotide analogue treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026038

Enrollment

Registered

2017-02-07

Start date

2017-01-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HBV carrier

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HBV carriers with NA treatment

Exclusion criteria

Exclusion criteria: HBVDNA breakthrough

Design outcomes

Primary

Measure	Time frame
The rate of patients who showed low HBsAg and HBcrAg during NA treatment	—

Secondary

Measure	Time frame
Predicting factors	—

Countries

Japan

Contacts

Public ContactMakoto Arai

Chiba University Hospital Gastroenterology

araim-cib@umin.ac.jp043-226-2083

Outcome results